Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof

Abstract

A method for treating a disease or for treating a symptom of a disease, or a combination of both, the disease being caused or aggravated by microorganisms includes: treating the disease, treating the symptom of the disease, or reducing the duration of the disease, or a combination of both by administering a barrier-forming composition in a therapeutically effective amount to a surface, the surface comprising a mammal mucosa, the mammal being infected with the disease or experiencing symptoms of the disease caused or aggravated by the microorganisms. The barrier-forming composition includes an antimicrobial. Upon administering the composition, the method includes forming a barrier coating on the surface that is active to kill or neutralize microorganisms encountered by the barrier coating. A composition with an agent active for relieving symptoms of a disease is also included.

1 . A method for treating a disease or for treating a symptom of a disease, or a combination of both, the disease being caused or aggravated by microorganisms, comprising:
 treating the disease, treating the symptom of the disease, or reducing the duration of the disease, or both, by administering a barrier-forming composition in a therapeutically effective amount to a surface, the surface comprising a mammal mucosa, the mammal being infected with the disease or experiencing symptoms of the disease caused or aggravated by the microorganisms;   the barrier-forming composition comprising an antimicrobial;   forming a barrier coating on the surface that is active to kill or neutralize microorganisms encountered by the barrier coating.   
     
     
         2 . The method of  claim 1 , further comprising effectively reducing the microbial load on the surface. 
     
     
         3 . The method of  claim 1 , further comprising reducing duration, frequency, or severity of the disease or one or more symptoms of the disease. 
     
     
         4 . The method of  claim 1 , further comprising reducing duration, frequency, or severity of one or more of cough, sore throat, and fever. 
     
     
         5 . The method of  claim 1 , wherein the disease is one or more diseases selected from the group consisting of: influenza, rhinovirus, bacterial upper or lower respiratory tract infections, viral upper or lower respiratory tract infections, Streptococcus infections, Staphylococcus infections, and ventilator associated pneumonia. 
     
     
         6 . The method of  claim 1 , wherein the disease is an upper respiratory infection. 
     
     
         7 . The method of  claim 3 , wherein the one or more symptoms comprise at least one of the following: runny nose, nausea, cough, headache, sneezing, sinus pressure, aches and pains, watery eyes, sore throat, sinus congestion, chills, vomiting, malaise, fatigue, rhinorrhea, and fever. 
     
     
         8 . The method of  claim 1 , wherein multiple symptoms of an upper respiratory infection are treated by administering the composition. 
     
     
         9 . The method of  claim 1 , further comprising administering the barrier-forming composition in the therapeutically effective amount to the surface, for one time or more, for at least two consecutive 24 hour periods. 
     
     
         10 . The method of  claim 1 , further administering the barrier-forming composition in the therapeutically effective amount to the surface three or more times in a 24 hour period for at least two consecutive 24 hour periods. 
     
     
         11 . The method of  claim 1 , wherein there is about 25% to about 99% reduction of the microbial burden from about one to about six hours after the administering step. 
     
     
         12 . The method of  claim 1 , wherein the mucosa is one or more of an oral, nasal, or pharyngeal mucosa. 
     
     
         13 . The method of  claim 1 , wherein the barrier layer has antimicrobial cidal or static activity for a duration of about six to about twenty-four hours. 
     
     
         14 . The method of  claim 1 , wherein the barrier-forming composition is applied by spraying. 
     
     
         15 . The method of  claim 1 , wherein the antimicrobial agent is a broad-spectrum antimicrobial. 
     
     
         16 . The method of  claim 1 , wherein the microorganisms are selected from the group consisting of:  Candida, Pneumonia,  MRSA,  Streptococcus, P. gingivalis, S. pyogenes, S. pneumonia, S. mutans, S. aureus, Y. enterocolitica, Acinetobacter bumanii, Streptococcus sanguis, S. oralis, S. mitis, S. salivarius, S. gordonii, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum, C. albicans, C. krusei, C. tropicalis, C. glabrata,  microorganisms that cause upper respiratory infections, microorganisms that cause lower respiratory infections, HIV, rhinovirus, EBV, and influenza viruses. 
     
     
         17 . The method of  claim 1 , wherein the microorganisms are selected from the group consisting of:  Candida, Pneumonia,  MRSA,  Streptococcus, P. gingivalis, S. pyogenes, S. pneumonia, S. mutans, S. aureus, Y. enterocolitica, Acinetobacter bumanii, Streptococcus sanguis, S. oralis, S. mitis, S. salivarius, S. gordonii, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum, C. albicans, C. krusei, C. tropicalis, C. glabrata,  HIV, EBV, influenza viruses, microorganisms that cause upper respiratory infections, microorganisms that cause lower respiratory infections,  Centipeda periodontii, Eikenella corrodens, Enterobacteriaceae, Fusobacterium nucleatum  subsp.  nucleatum, Fusobacterium nucleatum  subsp.  polymorphum, Fusobacterium nucleatum  subsp.  vincentii, Fusobacterium periodonticum, Porphyromonas endodontalis, Prevotella  ( Bacteroides )  melaninogenica, Prevotella intermedia, Bacteroides  ( Bacteroides )  loescheii, Solobacterium moorei, Tannerella forsythia  ( Bacteroides forsythus ),  Treponema denticola, Clostridium difficile, Bordetella pertussis, Burkholderia, Aspergillus fumigatus, Penicillium  spp,  Cladosporium,  HPV, cold,  Klebsiella pneumoniae, Salmonella choleraesuis, Escherichia coli  (0157:H7),  Trichophyton mentagrophytes,  Rhinovirus, Respiratory Syncytial Virus, Poliovirus Type 1, Rotavirus Wa, Influenza A Virus, Herpes Simplex Virus Types 1 & 2, and Hepatitis A Virus. 
     
     
         18 . The method of  claim 1 , wherein the antimicrobial agent is a monoquaternary ammonium compound. 
     
     
         19 . The method of  claim 1 , wherein the barrier coating is active to trap, and kill or neutralize microorganisms encountered by the barrier coating for a duration of at least one hour. 
     
     
         20 . The method of  claim 1 , wherein the barrier-forming composition comprises a humectant, an antimicrobial, and optionally a gum, wherein the gum, if present, is present in an amount of about 0.01% to about 0.4% by weight of the total barrier-forming composition. 
     
     
         21 - 30 . (canceled)